Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Stimulation of neurogenesis from Müller glia with AAV-delivered neurogenic transcription factors in adult mice.
Author Affiliations & Notes
  • Marina Pavlou
    Biological Structure, University of Washington, Seattle, Washington, United States
  • Marlene Probst
    Biological Structure, University of Washington, Seattle, Washington, United States
  • Aric Prieve
    Biological Structure, University of Washington, Seattle, Washington, United States
  • Thomas A Reh
    Biological Structure, University of Washington, Seattle, Washington, United States
  • Footnotes
    Commercial Relationships   Marina Pavlou None; Marlene Probst None; Aric Prieve None; Thomas Reh None
  • Footnotes
    Support  Foundation Fighting Blindness (REH) TA-RM-0321-0801-UWA-TRAP (Reh); Gilbert Family Foundation (Reh); NATIONAL EYE INSTITUTE, 2 R01 EY021482 (Reh), Weill Neurohub Fellowship (Pavlou).
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3329. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marina Pavlou, Marlene Probst, Aric Prieve, Thomas A Reh; Stimulation of neurogenesis from Müller glia with AAV-delivered neurogenic transcription factors in adult mice.. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3329.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Loss of neurons due to damage or disease is irreversible in humans and most mammals. Although we are incapable of regenerating neuronal tissue, other species such as fish and amphibians can regenerate their retina by employing developmental transcription programs that drive proliferation of support cells, which act as a progenitor pool for subsequent neurogenesis. We previously used transgenic mice to express neurogenic transcription factors in mouse Müller glia (MG) of acutely injured retinas to drive neurogenesis. Now we demonstrate that new lineage-traced neurons can be generated when these factors are delivered with viral vectors in vivo.

Methods : A mouse line with inducible MG-specific expression of TdTomato was used to lineage trace MG-derived progeny. Mice were intravitreally injected with adeno-associated viral (AAV) vectors with an inducible payload to drive expression of different combinations of TFs: Ascl1, Ascl1-Atoh1 or Ascl1-Atoh7. After a 2-6 week incubation period, the mice were injected with tamoxifen to induce the expression of the vector-borne TFs in MG. From this point on, mice received EdU water ad libitum to label newborn cells. To injure the retina, mice were intravitreally injected with an excitotoxic dose of NMDA, followed by an intravitreal injection of Trichostatin-A. Three weeks later, the number and types of glial-derived neurons were assessed via histology and scRNA-seq.

Results : The first step towards neurogenesis is the dedifferentiation of MG into a progenitor state that proliferates in response to injury. Histological analysis showed that following injury, MG re-entered the cell-cycle when injected with AAV vectors expressing any of the three TF combinations; untreated MG did not. Furthermore, AAV-borne expression of Ascl1 produced Otx2+/Pcp4+ bipolar neurons, whereas Ascl1-Atoh1/7 led to both HuC/D+ or Otx2+/Pcp4+ neurons. The production of new neurons was verified via lineage tracing MG-derived progeny and EdU incorporation. This was further corroborated by scRNA-seq of lineage-traced MG, showing that the classes of neurons obtained from AAV-treated retinas phenocopied the neurons obtained from glia using only transgenic methods.

Conclusions : Our results show for the first time that AAV-delivered TFs can stimulate neurogenesis from MG after injury in the adult mouse retina, bringing together AAV-mediated gene therapy and regenerative medicine.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×